Antipsychotic medications for schizophrenia

JAMA - Journal of the American Medical Association

Volumn 312, Issue 14, 2014, Pages 1467-1468

  Fleischhacker, W Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL DECANOATE; PALIPERIDONE; RISPERIDONE; DRUG DERIVATIVE; HALOPERIDOL; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PALMITIC ACID DERIVATIVE;

DRUG EFFICACY; DRUG SAFETY; HUMAN; INJECTION SITE REACTION; LETTER; PHASE 3 CLINICAL TRIAL (TOPIC); RECURRENCE RISK; SCHIZOPHRENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; FEMALE; MALE; NOTE;

ANTIPSYCHOTIC AGENTS; FEMALE; HALOPERIDOL; HUMANS; ISOXAZOLES; MALE; PALMITATES;

EID: 84907702272     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.10109     Document Type: Letter

References (5)

1. McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: A randomized clinical trial. JAMA. 2014;311(19):1978-1987.
2. Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2012;15(1):107-118.
3. Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73 (5):617-624.
4. Leucht S, TardyM, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review andmeta-analysis. Lancet. 2012;379(9831):2063-2071.
5. Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1):16-22.